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Hypocrellin A has gained much attention in recent years due 
to its light-induced antitumor, antifungal and antiviral acti-
vities. Here we report that hypocrellin A exerts immunom-
odulatory effects on MHC-restricted presentation of anti-
gen. Hypocrellin A inhibited class II-MHC restricted pre-
sentation of exogenous antigen, but not class I MHC-re-
stricted presentation of exogenous antigen, in dendritic cells. 
Hypocrellin A also inhibited the cytosolic pathway of endoge-
nous antigen presentation. However, hypocrellin A did not in-
hibit the expression of class I and class II MHC molecules on 
dendritic cells (DCs), the phagocytic activity of DCs, or the 
H-2K
b-restricted presentation of a synthetic peptide, SIIN-
FEKL. These results show that hypocrellin A differentially 
modulates the MHC-restricted antigen presentation path-
ways.
[Immune Network 2011;11(6):412-415]
Hypocrellin A is a naturally occurring perylenequinone com-
pound  isolated  from  the  stromata  of  Hypocrella  bambusae 
and Shiraia bambusae, which are parasitic fungi of bamboo 
(1). Hypocrellin A has long been known as an excellent pho-
tosensitizer and has gained much attention in recent years be-
cause of its light-induced antitumor, antifungal and antiviral 
activities (2-7). Hypocrellin A appears to exert photodynamic 
anticancer and antiviral activities through its abilities to gen-
erate reactive oxygen species and to inhibit protein kinase C 
activity (8-10). Hypocrellin A has also been shown to exert 
antimicrobial  and  antileishmanial  activities  in  vitro ( 1 1 ) .
    The present study reports that hypocrellin A differentially 
modulates MHC-restricted antigen presentation pathways. To 
examine the effects of hypocrellin A on the MHC-restricted 
antigen presentation, DC2.4 cells, a dendritic cell (DC) cell 
line, were incubated with hypocrellin A for 2 h, and then bio-
degradable microspheres containing ovalbumin (OVA, 50μg/ 
ml as OVA) were added to the cultures for 2 h. The process 
used to fabricate OVA-containing biodegradable microspheres 
was previously described in detail (12). The cells were then 
fixed  with  paraformaldehyde  and  washed  thoroughly  with 
P B S .  T h e  a m o u n t s  o f  O V A  p e p t i d e s  p r e s e n t e d  v i a  c l a s s  I  
MHC molecules were assessed in B3Z cells (H-2
b), which ex-
press β-galactosidase upon recognition of H-2K
b-OVA pep-
tide complexes, as described previously (13). The effects of 
hypocrellin A on the class II MHC-restricted presentation of 
exogenous OVA were examined in bone marrow-derived DCs 
(BM-DCs), which were generated from BM cells of BALB/c 
mice  (H-2
d)  b y  c u l t u r i n g  6  d a y s  i n  t h e  p r e s e n c e  o f  2 0 0  
units/ml of GM-CSF. After culturing BM-DCs with biodegra-
dable microspheres containing OVA (50μg/ml as OVA) for 
2 h, the BM-DCs were fixed with paraformaldehyde, washed, 
and then co-cultured with DOBW cells, which express IL-2 
upon  recognition  of  I-A
d-OVA  peptide  complexes,  as  de-
scribed previously (14). As shown in Fig. 1A, hypocrellin A 
did not inhibit class I MHC-restricted presentation of exoge-
nous  OVA.  However,  hypocrellin  A  dose-dependently  in-
hibited  class  II  MHC-restricted  presentation  of  exogenous 
OVA  (Fig.  1B).  The  IC50 w a s  a p p r o x i m a t e l y  8 0  n M .  T h e s e  
results show that hypocrellin A preferentially inhibits the class 
II MHC-restricted presentation pathway of exogenous antigen.
　The effects of hypocrellin A on the cytosolic pathway of 
endogenous antigen presentation were also examined in DCs. 
In  this  experiment,  DC2.4  cells  were  incubated  with  hypo-Immunomodulatory Effect of Hypocrellin A
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Figure 1. Effects of hypocrellin A on the MHC-restricted presentation of exogenous OVA.  (A) DC2.4 cells were incubated with the indicated 
amounts of hypocrellin A for 2 h, and then biodegradable microspheres containing OVA (50μg/ml as OVA) were added to the cultures for 
2 h. The cells were then fixed with paraformaldehyde, and the amounts of OVA peptides presented on MHC class I molecules were assessed 
by a LacZ T cell activation assay using OVA-specific CD8 T cell hybridoma B3Z cells. (B) BM-DCs generated from bone marrow cells of BALB/c 
mice were incubated with the indicated amounts of hypocrellin A for 2 h, and then biodegradable microspheres containing OVA (50μg/ml 
as OVA) were added to the cultures for 2 h. The cells were then washed, fixed with paraformaldehyde, and the amounts of OVA peptides 
presented on MHC class II molecules were assessed using OVA-specific CD4 T cell hybridoma DOBW cells.
Figure 2. Effects of hypocrellin A on the cytosolic pathway of endogenous antigen presentation. (A) DC2.4 cells were incubated with the indicated 
amounts of hypocrellin A for 2 h, washed, and then soluble OVA was loaded into cytosol by osmotic shock as described previously (13). After 
2-h incubation, the amounts of H-2K
b-OVA peptide complexes were assessed using OVA-specific CD8 T cell hybridoma B3Z cells. (B) The 
indicated amounts of hypocrellin A were added to cultures of DC2.4 cells that had been infected with rVV-OVA (MOI 10). After 6 h, the DCs 
were washed, fixed with paraformaldehyde, and then the capacity to activate OVA-specific CD8 T cells was assessed using OVA-specific CD8 
T cell hybridoma B3Z cells.
crellin A for 2 h, washed, and then soluble OVA was loaded 
into  the  cytosol  by  osmotic  shock  as  described  previously 
(13). After 2-h incubation, the amounts of H-2K
b-OVA peptide 
complexes were assessed with B3Z cells. As shown in Fig. 
2A, hypocrellin A profoundly inhibited class I MHC-restricted 
presentation of endogenous OVA. To confirm the inhibitory 
effects  of  hypocrellin  A  on  the  endogenous  antigen  pre-
sentation pathway, recombinant Vaccinia virus-encoded OVA 
(rVV-OVA) was utilized as another source of cytosolic antigen 
as described previously (14). Briefly, DC 2.4 cells were in-
fected with rVV-OVA at MOI of 10 for 20 min and then in-
cubated with different concentrations of hypocrellin A for 6 
h. The amounts of OVA peptides presented on class I MHC 
molecules were then assessed using B3Z cells. As shown in 
Fig.  2B,  hypocrellin  A  dose-dependently  inhibited  class  I 
MHC-restricted  presentation  of  endogenous  OVA.  The  IC50 
was  approximately  200  nM.
　To prove that hypocrellin A inhibits an intracellular event Immunomodulatory Effect of Hypocrellin A
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Figure 3. Hypocrellin A does not inhibit the expression levels of class I and class II MHC molecules or the presentation of a synthetic OVA 
peptide SIINFEKL. Hypocrellin A (2,000 nM) was added to cultures of DC2.4 cells for 2 h. The cells were harvested, washed, and then stained 
with anti-mouse H-2K
b monoclonal antibody (A) or anti-I-A
b monoclonal antibody (B). The shaded histograms represent the expression levels 
of class I and class II MHC molecules in the presence of hypocrellin A, and the thick lines represent the expression levels of class I and class 
II MHC molecules in the absence of hypocrellin A. The dotted lines represent isotype controls. (C) Indicated amounts of hypocrellin A were 
added to cultures of DC2.4 cells together with the antigenic peptide of OVA, SIINFEKL. The cells were harvested, washed, and then the amount 
of SIINFEKL-H-2K
b complex was measured by a LacZ T cell activation assay using OVA-specific CD8 T cell hybridoma B3Z cells.
in  the  antigen  processing  pathways,  we  examined  whether 
hypocrellin A inhibited the expression of MHC molecules on 
DCs. DC2.4 cells were incubated with hypocrellin A (2,000 
nM) for 2 h, and then the expression levels of class I and 
class  II  MHC  molecules  were  determined  using  anti-H-2K
b 
and anti-I-A
d monoclonal antibodies. As shown in Fig. 3A and 
B, the expression levels of H-2K
b and I-A
d molecules were 
not decreased by hypocrellin A to a discernable degree. We 
then  examined  whether  hypocrellin  A  inhibited  the  phag-
o c y t i c  a c t i v i t y  o f  D C s  u s i n g  m icrospheres  containing  both 
OVA and FITC; we found that it did not inhibit the phagocytic 
activity of DCs (data not shown). In addition, we examined 
the effects of hypocrellin A on the class I MHC-restricted pre-
sentation  of  the  H-2K
b- b i n d i n g  O V A  p e p t i d e ,  S I I N F E K L .  A s  
shown in Fig. 3C, hypocrellin A did not inhibit presentation 
of  exogenously  added  synthetic  peptide,  SIINFEKL.
　Two  distinct  pathways  have  been  identified  for  the 
MHC-restricted  presentation  of  exogenous  antigens  (15).  In 
the classical paradigm of exogenous antigen presentation by 
professional APCs, antigens internalized by phagocytosis are 
processed  and  loaded  on  class  II  MHC  molecules  in  a 
post-Golgi compartment. Professional APCs, however, proc-
ess  exogenous  antigens  for  presentation  on  class  I  MHC 
molecules.  This  process,  termed  cross-presentation,  is  cur-
rently  recognized  as  an  obligatory  mechanism  for  the  gen-
eration of CTL responses to antigens that are expressed only 
in  nonprofessional  antigen-presenting  cells  (APCs)  (16,17). 
V a r i o u s  m e c h a n i s m s  h a v e  b e e n  p r o p o s e d  t o  e x p l a i n  c r o s s -  
presentation such as the cytosolic alternate pathway, the va-
cuolar alternate MHC-I pathway, and the fusion of the endo-
plasmic reticulum (ER) with the endosome/phagosome (18,19). 
It was recently shown that phagocytosed OVA-microspheres 
are cross-presented via an alternate MHC-I processing path-
way in DCs (12). It appears that hypocrellin A does not in-
hibit  the  alternative  pathway  of  exogenous  antigen  pre-
sentation, which involves transfer of exogenous antigenic pro-
teins  from  the  vacuolar  compartment  to  the  cytosol,  where 
they are partially digested by the proteosome, transferred into 
ER by transporter associated with antigen presentation (TAP), 
and then loaded on class I MHC molecules (20). However, 
hypocrellin A does inhibit the classical cytosolic pathway of 
endogenous antigen presentation, as shown in Fig. 2. Thus, 
it appears that hypocrellin A inhibits a post-Golgi compart-
ment in the exogenous antigen processing pathway, probably 
inhibiting intraphagosomal processing of the antigen and ex-
port  of  the  antigen  from  the  phagosome  to  the  cytosol. 
Although the precise mechanism underlying the inhibitory ac-
tivity of hypocrellin A has not been elucidated, it is tempting 
to speculate that the mechanism for the inhibition of the class 
II MHC-restricted antigen processing pathway by hypocrellin 
A is different from that of chloroquine or ammonium chlor-
ide, which inhibit the class II MHC-restricted presentation of 
exogenous antigens by reducing the acidification of the endo-
cytic  compartment  (21),  because  hypocrellin  A  is  a  hydro-
phobic  peryloquinone  derivative  (22). Immunomodulatory Effect of Hypocrellin A
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